Lice
Treatment Market Research Report, by type (pediculosis capitis, pediculosis
corporis, pediculosis pubis), treatment (OTC products, prescription
medications), distribution channel (online platform, hospitals & clinics) –
Global Forecast till 2023
Lice are parasites that grow mostly in the
head or pubic areas and feed on human blood. These parasites are increasingly
becoming resistant to traditional methods of treatments which has created an
urgent need for the development of effective treatment options. Market Research
Future (MRFR) has recently published an in-depth report on the global Lice Treatment Market and has
projected a steady CAGR of 6.5% in the market over the forecast period of
2018-2023.
The prevalence of lice parasites
contamination is increasing perpetually worldwide which is the prime factor
boosting the growth of the lice treatment market. New product launches, elevation in level of awareness, and easy
availability of lice treatment products is fueling the growth of the market.
Growing R&D activities by pharmaceutical companies to come up effective
compounds which can effective kill these more than ever resistant parasites is
likely to provide attractive opportunities to the market.
Segmentation
The global lice treatment market is
segmented based on type, treatment, and end user.
By type, the lice treatment market has been
segmented into pediculosis capitis, pediculosis corporis, and pediculosis
pubis.
By treatment, the lice treatment market has
been segmented into two, i.e., OTC (over the counter) products and prescription
medications. The OTC medication segment has been further segmented into
permethrin, pyrethrin, and others. The
prescription segment has been further segmented into ivermectin, spinosad,
malathion, and others.
By distribution channel, the lice treatment
market has been segmented into hospitals & clinics, retail pharmacies, and
online platform.
Regional
Analysis
Region-wise, the lice treatment market has
been segmented into the Americas, the Middle East & Africa (MEA), Asia
Pacific (APAC), and Europe.
The global lice treatment market is led by
the Americas. Surging prevalence of Pediculosis Capitis, Pediculosis Pubis, and
Pediculosis Corporis in the region has supported the growth of the North
America lice treatment market. Rising child population in the region who are
more prone to lice are generating demand for lice treatment. Additionally, high
healthcare expenditure and availability of favorable reimbursement schemes in
the region is supporting the growth of the market. The major market players are
present in the Americas are actively engaged in product development and
innovation which further aids the expansion of the Americas market.
Europe follows the Americas closely and is
driven by similar factors as the Americas. A well-developed healthcare
infrastructure, rising awareness, and rapidly expanding pharmaceutical sector
in the region is boding well for the market growth.
The APAC lice treatment market is
anticipated to expand at the fastest CAGR over the forecast period. High
contamination rate of lice and lack of awareness regarding personal hygiene has
spurred the demand for lice treatment in the region. Increasing healthcare
expenditure and the rising penetration of market players in the region can be
credited for the growth of the market.
The MEA lice treatment market accounts for
relatively least share of the market. Lack of awareness in the underdeveloped
countries of the region, especially in Africa and low healthcare penetration is
restricting the growth of the lice treatment market. The Middle East accounts
for the foremost share of the MEA market. Rising healthcare spending by the
governments in the GCC countries, upsurge in awareness, and increasing presence
of market players in the region are favoring the market growth in the region.
Competitive
Landscape
GlaxoSmithKline, Omega Pharma, Pfizer,
AkzoNobel N.V., Dow AgroSciences LLC, Johnson & Johnson, Topaz
Pharmaceuticals Inc., Bayer HealthCare, Elanco, Suven Life Sciences, Sanofi,
Insight Pharmaceuticals, Alliance Pharmaceuticals Ltd., and Taro Pharmaceuticals
are the key players in the global lice treatment market.
Industry
Updates
February 2019 - ICB Pharma, a company
specializing in the field of pest innovations, crop protection, and other
fields of healthcare, announced the launch of a new head-lice product - Nitolic Head Lice and
Nits Treatment Kit. The product is free from pesticide and is capable of
eliminating all active development stages of head lice in 60 minutes. Moreover,
the product is formulated to kill the new generation of lice known as 'super
lice' which are resistant to traditional methods.
No comments:
Post a Comment